Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TRIB 
Trinity Biotech plc (TRIB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: TRIB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.08% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.15M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta 0.81 | 52 Weeks Range 0.48 - 3.44 | Updated Date 06/30/2025 |
52 Weeks Range 0.48 - 3.44 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -51.64% | Operating Margin (TTM) -42.73% |
Management Effectiveness
Return on Assets (TTM) -10.53% | Return on Equity (TTM) -1913.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 107745076 | Price to Sales(TTM) 0.2 |
Enterprise Value 107745076 | Price to Sales(TTM) 0.2 | ||
Enterprise Value to Revenue 1.75 | Enterprise Value to EBITDA -6.06 | Shares Outstanding 18632000 | Shares Floating 360917114 |
Shares Outstanding 18632000 | Shares Floating 360917114 | ||
Percent Insiders 12.01 | Percent Institutions 4.62 |
Analyst Ratings
Rating 1 | Target Price 3 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Trinity Biotech plc
Company Overview
History and Background
Trinity Biotech plc, founded in 1992, is a global diagnostics company specializing in autoimmune, clinical chemistry, and infectious disease testing. It has grown through strategic acquisitions and product development.
Core Business Areas
- Clinical Chemistry: Develops, manufactures, and markets a range of clinical chemistry reagents and instruments used for routine blood analysis.
- Infectious Diseases: Focuses on developing and marketing diagnostic tests for infectious diseases like HIV and sexually transmitted infections.
- Autoimmunity: Offers a range of diagnostic tests for autoimmune diseases, aiding in the diagnosis and monitoring of conditions like rheumatoid arthritis.
Leadership and Structure
Trinity Biotech plc's leadership team consists of a Chief Executive Officer, Chief Financial Officer, and other senior executives. The organizational structure comprises various departments, including R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Premier Resolution: A HPLC system for hemoglobin testing. Competitors include Bio-Rad and Sebia. Revenue figures are not publicly available, however HPLC market share is fragmented.
- Uni-Gold Recombigen HIV: A rapid HIV point-of-care test. Market share data is not readily available, but is a smaller segment versus automated platforms. Competitors include Abbott and Roche.
Market Dynamics
Industry Overview
The diagnostics industry is experiencing growth due to increasing healthcare expenditure, an aging population, and technological advancements.
Positioning
Trinity Biotech plc holds a niche position in specialized diagnostics, focusing on specific segments of the market. They compete with larger, diversified players.
Total Addressable Market (TAM)
The global diagnostics market is estimated to be worth hundreds of billions of dollars. Trinity Biotech plc is positioned within specific segments of this TAM, such as infectious disease and autoimmune testing.
Upturn SWOT Analysis
Strengths
- Specialized diagnostics focus
- Established distribution network
- Proprietary technologies
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on specific product lines
- Exposure to regulatory changes
Opportunities
- Expansion into emerging markets
- Development of new diagnostic tests
- Strategic partnerships and acquisitions
Threats
- Increased competition from larger players
- Technological obsolescence
- Economic downturns
Competitors and Market Share
Key Competitors
- ROCHE
- ABT
- BIIB
- TMO
- DHR
Competitive Landscape
Trinity Biotech plc faces competition from larger, more diversified diagnostic companies. Its competitive advantage lies in its specialized focus and proprietary technologies.
Major Acquisitions
Fiomi Diagnostics
- Year: 2024
- Acquisition Price (USD millions): 5.2
- Strategic Rationale: Expand into adjacent markets, providing increased reach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been influenced by acquisitions and product development.
Future Projections: Future growth depends on the successful development and commercialization of new products and strategic partnerships.
Recent Initiatives: Data not specified.
Summary
Trinity Biotech plc is a smaller player in the diagnostics market with a specialized focus. While its strategic acquisitions show promise, the company faces challenges from larger competitors and regulatory changes. Its ability to successfully develop and commercialize new products will be crucial for future growth. It has specialized products however, it does need more funding to ensure its reach. Regulatory and commercial conditions should be followed closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Trinity Biotech plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1995-08-18 | President, CEO, Company Secretary & Director Mr. John Gillard | ||
Sector Healthcare | Industry Medical Devices | Full time employees 401 | Website https://www.trinitybiotech.com |
Full time employees 401 | Website https://www.trinitybiotech.com | ||
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.